These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29581791)

  • 1. Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
    Goag EK; Lee JM; Chung KS; Kim SY; Leem AY; Song JH; Jung JY; Park MS; Chang YS; Kim YS; Chang J; Kim EY
    J Cancer; 2018; 9(6):1113-1120. PubMed ID: 29581791
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
    Zhou J; Li Y; Zhang Y; Dai H; Guo S
    Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
    Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM
    Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
    Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
    Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
    Huang YH; Hsu KH; Tseng JS; Chen KC; Hsu CH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
    Cancer Res Treat; 2018 Oct; 50(4):1294-1303. PubMed ID: 29334606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
    Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
    Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endobronchial ultrasound-guided re-biopsy of non-small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment.
    Hong KS; Cho J; Jang JG; Jang MH; Ahn JH
    Thorac Cancer; 2023 Feb; 14(4):363-370. PubMed ID: 36525475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.
    Nam Y; Kim HC; Kim YC; Jang SH; Lee KY; Lee SY; Lee SH; Lee SY; Yoon SH; Ryu JS; Jang TW; Chang YS; Kim SJ; Park CK; Lee JE; Jung CY; Choi CM
    Thorac Cancer; 2021 Mar; 12(6):890-898. PubMed ID: 33529490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
    Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
    Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.
    Kawamura T; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Nakajima T; Ohde Y; Endo M; Takahashi T
    Cancer Sci; 2016 Jul; 107(7):1001-5. PubMed ID: 27145431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
    Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
    Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
    Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
    Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring
    Tanaka K; Nosaki K; Otsubo K; Azuma K; Sakata S; Ouchi H; Morinaga R; Wataya H; Fujii A; Nakagaki N; Tsuruta N; Takeshita M; Iwama E; Harada T; Nakanishi Y; Okamoto I
    Oncotarget; 2017 Sep; 8(40):68123-68130. PubMed ID: 28978102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.
    Matsuo N; Azuma K; Sakai K; Hattori S; Kawahara A; Ishii H; Tokito T; Kinoshita T; Yamada K; Nishio K; Hoshino T
    Sci Rep; 2016 Nov; 6():36458. PubMed ID: 27811988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world.
    Li H; Wang J; Zhang G; Li Y; Lin L; Yang H; Zhou J; Zhang L; Lv D
    J Thorac Dis; 2020 Mar; 12(3):550-557. PubMed ID: 32274120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer.
    Ichihara E; Hotta K; Kubo T; Higashionna T; Ninomiya K; Ohashi K; Tabata M; Maeda Y; Kiura K
    Oncotarget; 2018 Jun; 9(50):29525-29531. PubMed ID: 30034635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.